How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

732 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Whey Protein Study

(including severe depression, lithium treatment, schizophrenia, severe behavioural disorders) Vegetarians & Vegans Medication Exclusion Criteria: Orlistat (Xenical) Oral antidiabetics, insulin Rimonabant (Acomplia) Digoxin, anti-arrhythmics Sibutramine (Reductil) Tricyclic antidepressants, neuroleptics Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2014 Clinical Trials

182. The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient

supplements, vitamins and herbal products at least 3 months before and throughout the intervention Exclusion Criteria: people who have used n-3 Fatty Acid Supplementation in last 3 months, having chronic renal disease , GI disease, Hepatobiliary diseases, hematological disorders, hypo- or hyperthyroidism, type 1 diabetes, treatment with orlistat or sibutramine for weight loss, pregnancy and lactation, treatment with insulin or Thiazolidinediones. Contacts and Locations Go to No Contacts or Locations

2014 Clinical Trials

183. Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome

, ardeparin, certoparin, lepirudin, bivalirudin Other anticoagulants: argatroban, apixaban, dabigatran, rivaroxaban, warfarin, acenocoumarol, dicumarol, phenindione and other anticoagulants Lithium Selective serotonin and norepinephrine reuptake inhibitors: milnacipran, fluoxetine, paroxetine, nefazodone, citalopram, clovoxamine, escitalopram, flesinoxan, femoxetine, duloxetine, venlafaxine, vilazodone, sibutramine, desvenlafaxine Anticonvulsants: phenytoin, paraldehyde, valproic acid, carbamazepine

2014 Clinical Trials

184. Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation

with attending physician) Liver disease; history of alcoholism. Known or suspected allergy to liraglutide Contraindications to liraglutide: patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 Patients with a history of pancreatitits Patients that have been treated with drugs that promote weight loss (e.g., Xenical® [orlistat], Meridia® [sibutramine], Acomplia® [rimonabant], Acutrim® [phenylpropanolamine], or similar over

2014 Clinical Trials

185. Effects of Obex in Overweight and Obese Patients

with chronic medical conditions requiring regular intake of any prescription medications. Used drugs for weight loss (e.g., Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanolamine], Accomplia [rimonabant], Alli [low-dose orlistat], or other similar over-the-counter weight loss remedies or medications) within 3 months of screening Are actively participating in, or have participated in a formal weight loss program within the last 3 months Contacts and Locations Go to Information from

2014 Clinical Trials

186. Associations between the GNB3 C825T polymorphism and obesity-related metabolic risk factors in Korean obese women. (PubMed)

of or list at on weight loss with sibutramine. A sample of 111 obese women were divided into T-carriers (CT/TT) or a homozygous CC group, according to the presence of the 825T allele at GNB3. These groups were compared to determine their associations with obesity-related metabolic risk factors, i.e., fasting plasma glucose, serum lipids, serum insulin/insulin resistance, and abdominal fat amounts.The allele frequencies of the GNB3 polymorphism were C allele = 59.5% and T allele = 40.5%. The T allele

2014 Journal of endocrinological investigation

187. A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. (PubMed)

A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. No long-term studies have compared centrally acting drugs for treating obesity.To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss.A prospective, randomized, placebo (PCB)-controlled study conducted at a single academic institution.A total of 174 obese premenopausal women.Participants randomly

2014 International Journal of Obesity

188. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome. (PubMed)

. Fifty overweight/obese women with PCOS were prescribed an energy-restricted diet, were instructed to exercise and were randomized to orlistat 120 mg tid or sibutramine 10 mg qd for 6 months.In normal weight women, treatment with metformin reduced the body mass index (BMI) and circulating androgens, improved markers of IR and lowered PAI-1 levels. In overweight/obese women, sibutramine and orlistat yielded comparable reductions in BMI and markers of IR. In contrast, the effects on the free androgen (...) index (FAI) differed (p=0.027): sibutramine reduced the FAI (p=0.005), whereas orlistat had no effect. The effects of sibutramine and orlistat on PAI-1 levels also differed (p=0.042): sibutramine reduced PAI-1 levels (p<0.001), whereas orlistat had no effect.Metformin and sibutramine, but not orlistat, reduce PAI-1 levels in PCOS. The reduction in circulating androgens during metformin and sibutramine treatment might be implicated in this decline.

2014 Hormones (Athens, Greece)

189. Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial. (PubMed)

in a large weight loss trial.Data from the Sibutramine Cardiovascular Outcomes (SCOUT) trial, including almost 10.000 overweight/obese high cardiovascular risk patients, were used. The relationship between total bilirubin level at screening and the primary outcome (i.e. non-fatal myocardial infarction, non-fatal stroke, resuscitated cardiac arrest or cardiovascular death) for the entire study period was investigated using Cox proportional hazards models. The population was divided into four groups based

2014 Nutrition, metabolism, and cardiovascular diseases : NMCD

190. Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. (PubMed)

Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise. We examined the relationship between early changes (both increases and decreases) in body weight and blood (...) . Post hoc subgroup analyses of weight change (categories) and blood pressure were performed overall and by treatment group (6-week sibutramine followed by randomized placebo or continued sibutramine). The primary outcome event (POE) was a composite of nonfatal myocardial infarction, nonfatal stroke, resuscitated cardiac arrest or cardiovascular death. Time-to-event analyses of the POE were performed using Cox regression models with factors for treatment, subgroups and interactions.During the initial

2014 International Journal of Obesity

191. Influence of eating behaviors on short-term weight loss by orlistat and anorectic agent. (PubMed)

Influence of eating behaviors on short-term weight loss by orlistat and anorectic agent. Little data exists concerning whether eating behaviors determine the response to orlistat treatment, especially with added anorectic agents. This study was a sub-investigation of a 12-week randomized controlled trial for the additive effect of orlistat on sibutramine treatment. The analysis presented here was restricted to 98 women who had fulfilled the protocol. The Dutch eating behavior questionnaire (...) in the treatment with orlistat and sibutramine. Subjects with less vulnerability to emotional cues had significantly more weight loss with orlistat treatment and anorectic agents. © 2013.

2014 Eating behaviors

192. The effect of anti-obesity drugs on waist circumference: a mixed treatment comparison.

The effect of anti-obesity drugs on waist circumference: a mixed treatment comparison. To use meta-analytic techniques to quantitatively evaluate the efficacy of orlistat and lorcaserin in the treatment of people who are overweight and obese.We identified publications from searches of electronic databases and extracted data from studies that compared orlistat or lorcaserin to lifestyle advice (standard care), placebo, sibutramine, rimonabant or metformin and collected information on waist

2014 obesity & metabolism

193. Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: Randomized placebo-controlled clinical trial of self-help and medication. (PubMed)

therapy (shCBT) and an anti-obesity medication (sibutramine), alone and in combination, and it is only the second placebo-controlled trial of any medication for BED to evaluate longer-term effects after treatment discontinuation. 104 obese patients with BED (73% female, 55% non-white) were randomly assigned to one of four 16-week treatments (balanced 2-by-2 factorial design): sibutramine (N = 26), placebo (N = 27), shCBT + sibutramine (N = 26), or shCBT + placebo (N = 25). Medications were (...) administered in double-blind fashion. Independent assessments were performed monthly throughout treatment, post-treatment, and at 6- and 12-month follow-ups (16 months after randomization). Mixed-models analyses revealed significant time and medication-by-time interaction effects for percent weight loss, with sibutramine but not placebo associated with significant change over time. Percent weight loss differed significantly between sibutramine and placebo by the third month of treatment and at post

Full Text available with Trip Pro

2014 Behaviour research and therapy

194. An Electronic Health Records Study of Long-Term Weight Gain Following Antidepressant Use. (PubMed)

hydrochloride, mirtazapine, nortriptyline hydrochloride, paroxetine hydrochloride, venlafaxine hydrochloride, and sertraline hydrochloride. As measures of assay sensitivity, additional index prescriptions examined included the antiasthma medication albuterol sulfate and the antiobesity medications orlistat, phentermine hydrochloride, and sibutramine hydrochloride. Mixed-effects models were used to estimate rate of weight change over 12 months in comparison with the reference antidepressant

Full Text available with Trip Pro

2014 JAMA psychiatry (Chicago, Ill.)

195. Change in body composition during a weight loss trial in obese adolescents. (PubMed)

index (BMI) change with TotFM (R = 0.70-0.91, P = 0.001) and WC change (R = 0.53-0.55, P < 0.001). Conclusions Weight loss in obese adolescents during a weight loss trial using lifestyle management and sibutramine was primarily from trunk FM. Although absolute LM increased in boys and decreased in girls, the percentage of weight that is LM increased for both boys and girls. Changes in BMI were more reflective of changes in FM than changes in WC.© 2013 The Authors. Pediatric Obesity © 2013

Full Text available with Trip Pro

2014 Pediatric obesity

196. A two-year randomized trial of obesity treatment in primary care practice. (PubMed)

replacements or weight-loss medication (orlistat or sibutramine), chosen by the participants in consultation with the PCPs, to potentially increase weight loss.Of the 390 participants, 86% completed the 2-year trial, at which time, the mean (±SE) weight loss with usual care, brief lifestyle counseling, and enhanced brief lifestyle counseling was 1.7±0.7, 2.9±0.7, and 4.6±0.7 kg, respectively. Initial weight decreased at least 5% in 21.5%, 26.0%, and 34.9% of the participants in the three groups (...) , respectively. Enhanced lifestyle counseling was superior to usual care on both these measures of success (P=0.003 and P=0.02, respectively), with no other significant differences among the groups. The benefits of enhanced lifestyle counseling remained even after participants given sibutramine were excluded from the analyses. There were no significant differences between the intervention groups in the occurrence of serious adverse events.Enhanced weight-loss counseling helps about one third of obese

Full Text available with Trip Pro

2011 NEJM

197. Pharmacotherapy for overweight/obesity in ethnic minorities and white Caucasians: a systematic review and meta-analysis (PubMed)

and White Caucasians. Data sources between 1990 and 2010 were searched including MEDLINE, EMBASE, Cochrane Controlled Trials Register, CINAHL and references cited in the included studies of other reviews. Eighteen RCTs that met the inclusion criteria were included in this review (6 sibutramine and 12 orlistat). A random effects model was used for meta-analysis. An indirect comparison of weight loss in sibutramine-treated patients in ethnic minorities was significantly lower than in White Caucasians

2011 EvidenceUpdates

198. Obesity

of the marketing authorisation for sibutramine (Reductil ® ) because the benefits no longer outweigh the risks. This CKS topic has been updated to reflect the EMEA's decision. Recommendations regarding when to consider prescribing sibutramine as well as its prescribing information and prescriptions have been removed. Issued in January 2010. October 2008 — updated. On 23 October 2008, the EMEA's CMHP recommended the suspension of the marketing authorisation for rimonabant (Acomplia ® ) because the benefits (...) no longer outweigh the risks. This CKS topic has been updated to reflect the EMEA's decision. Recommendations regarding when to consider prescribing rimonabant as well as its prescribing information and prescriptions have been removed. Issued in November 2008. July 2008 — minor update to incorporate the recommendation from NICE that rimonabant may now be prescribed as an alternative to orlistat or sibutramine. A scenario on prescribing rimonabant has been added. May 2008 — minor update to text

2012 NICE Clinical Knowledge Summaries

200. Unstable Angina (Diagnosis)

. Safety: Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. US Food and Drug Administration. October 8, 2010. Available at . Accessed: June 5, 2013. Soukoulis V, Boden WE, Smith SC Jr, O'Gara PT. Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res . 2014 Jun 6. 114(12):1944-58. . . Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical


To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>